Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

Figure 1: Prostate cancer – current and future market dynamics analysis
Figure 2: The author's assessment summary of key marketed and pipeline drugs for prostate cancer
Figure 3: Prostate cancer sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Prostate cancer sales across the US, Japan, and five major EU markets, by class, 2017–26
Figure 5: Generics sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017–26
Figure 6: Xtandi sales in prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 7: Pipeline next-generation hormone therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017–26
Figure 8: Autologous vaccine sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017–26
Figure 9: Targeted pipeline therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017–26
Figure 10: Patient-based forecast methodology for prostate cancer
Figure 11: Price sources and calculations, by country
Figure 12: DCVAC/PCa for prostate cancer – SWOT analysis
Figure 13: The author's drug assessment summary of DCVAC/PCa for prostate cancer
Figure 14: The author's drug assessment summary of DCVAC/PCa for prostate cancer
Figure 15: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 16: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 17: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 18: Jevtana for prostate cancer – SWOT analysis
Figure 19: The author's drug assessment summary of Jevtana for prostate cancer
Figure 20: The author's drug assessment summary of Jevtana for prostate cancer
Figure 21: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 22: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 23: Lynparza for prostate cancer – SWOT analysis
Figure 24: The author's drug assessment summary of Lynparza for prostate cancer
Figure 25: The author's drug assessment summary of Lynparza for prostate cancer
Figure 26: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 27: Provenge for prostate cancer – SWOT analysis
Figure 28: The author's drug assessment summary of Provenge for prostate cancer
Figure 29: The author's drug assessment summary of Provenge for prostate cancer
Figure 30: Provenge sales for prostate cancer in the US, 2017–26
Figure 31: Rubraca for prostate cancer – SWOT analysis
Figure 32: The author's drug assessment summary of Rubraca for prostate cancer
Figure 33: The author's drug assessment summary of Rubraca for prostate cancer
Figure 34: Rubraca sales for prostate cancer across the US and five major EU markets, by country, 2017–26
Figure 35: Tecentriq for prostate cancer – SWOT analysis
Figure 36: The author's drug assessment summary of Tecentriq for prostate cancer
Figure 37: The author's drug assessment summary of Tecentriq for prostate cancer
Figure 38: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 39: Trelstar sales for prostate cancer across the US and five major EU markets, by country, 2017–26
Figure 40: Xofigo for prostate cancer – SWOT analysis
Figure 41: The author's drug assessment summary of Xofigo for prostate cancer
Figure 42: The author's drug assessment summary of Xofigo for prostate cancer
Figure 43: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 44: Xtandi for prostate cancer – SWOT analysis
Figure 45: The author's drug assessment summary of Xtandi for prostate cancer
Figure 46: The author's drug assessment summary of Xtandi for prostate cancer
Figure 47: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 48: Yonsa for prostate cancer – SWOT analysis
Figure 49: The author's drug assessment summary of Yonsa for prostate cancer
Figure 50: The author's drug assessment summary of Yonsa for prostate cancer
Figure 51: Yonsa sales for prostate cancer in the US, 2017–26
Figure 52: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 53: Zytiga for prostate cancer – SWOT analysis
Figure 54: The author's drug assessment summary of Zytiga for prostate cancer
Figure 55: The author's drug assessment summary of Zytiga for prostate cancer
Figure 56: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 57: Apalutamide for prostate cancer – SWOT analysis
Figure 58: The author's drug assessment summary of apalutamide for prostate cancer
Figure 59: The author's drug assessment summary of apalutamide for prostate cancer
Figure 60: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 61: Darolutamide for prostate cancer – SWOT analysis
Figure 62: The author's drug assessment summary of darolutamide for prostate cancer
Figure 63: The author's drug assessment summary of darolutamide for prostate cancer
Figure 64: Darolutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 65: Ipatasertib for prostate cancer – SWOT analysis
Figure 66: The author's drug assessment summary of ipatasertib for prostate cancer
Figure 67: The author's drug assessment summary of ipatasertib for prostate cancer
Figure 68: Ipatasertib sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 69: Masitinib for prostate cancer – SWOT analysis
Figure 70: The author's drug assessment summary of masitinib for prostate cancer
Figure 71: The author's drug assessment summary of masitinib for prostate cancer
Figure 72: Masitinib sales for prostate cancer across the five major EU markets, by country, 2017–26
Figure 73: Relugolix for prostate cancer – SWOT analysis
Figure 74: The author's drug assessment summary of relugolix for prostate cancer
Figure 75: The author's drug assessment summary of relugolix for prostate cancer
Figure 76: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 77: Localized prostate cancer patients receiving each type of treatment, by country
Figure 78: Localized prostate cancer patients treated with pharmacological therapy + prostatectomy receiving neoadjuvant and/or adjuvant therapy
Figure 79: Localized prostate cancer patients treated with pharmacological therapy + radiotherapy receiving neoadjuvant, concurrent, and/or adjuvant therapy
Figure 80: Pharmacologically treated localized prostate cancer patients receiving each therapy type, by country
Figure 81: Top three regimens used in localized prostate cancer patients treated with ADT, by country
Figure 82: Locally advanced prostate cancer patients receiving each type of treatment, by country
Figure 83: Pharmacologically treated locally advanced prostate cancer patients receiving each therapy type, by country
Figure 84: Top three regimens used in locally advanced prostate cancer patients treated with ADT, by country
Figure 85: Metastatic castration-naïve prostate cancer patients receiving each type of treatment, by country
Figure 86: Pharmacologically treated metastatic castration-naïve prostate cancer patients receiving each therapy type, by country
Figure 87: Top three regimens used in metastatic castration-naïve prostate cancer patients treated with ADT, by country
Figure 88: Recurrent/progressive prostate cancer patients receiving each type of treatment at first line, by country
Figure 89: Recurrent/progressive prostate cancer patients receiving each type of treatment at second line, by country
Figure 90: Pharmacologically treated recurrent/progressive prostate cancer patients receiving each therapy type at first and second line
Figure 91: Top three first-line regimens for recurrent/progressive prostate cancer patients treated with ADT, by country
Figure 92: Top three second-line regimens for recurrent/progressive prostate cancer patients treated with ADT, by country
Figure 93: nmCRPC patients receiving each type of treatment at first line, by country
Figure 94: nmCRPC patients receiving each type of treatment at second line, by country
Figure 95: Pharmacologically treated nmCRPC patients receiving each therapy type at first line and second line
Figure 96: Top three first-line regimens for nmCRPC patients treated with ADT, by country
Figure 97: Top three second-line regimens for nmCRPC patients treated with ADT, by country
Figure 98: Top three first-line regimens for nmCRPC patients treated with chemotherapy, by country
Figure 99: Top three second-line regimens for nmCRPC patients treated with chemotherapy, by country
Figure 100: mCRPC patients receiving each type of treatment at first line, by country
Figure 101: mCRPC patients receiving each type of treatment at second line, by country
Figure 102: mCRPC patients receiving each type of treatment at third line, by country
Figure 103: Pharmacologically treated mCRPC patients receiving each therapy type at first line, second line, and third line
Figure 104: Top three first-line regimens for mCRPC patients treated with ADT, by country
Figure 105: Top three second-line regimens for mCRPC patients treated with ADT, by country
Figure 106: Top three third-line regimens for mCRPC patients treated with ADT, by country
Figure 107: Top three first-line regimens for mCRPC patients treated with chemotherapy, by country
Figure 108: Top three second-line regimens for mCRPC patients treated with chemotherapy, by country
Figure 109: Top three third-line regimens for mCRPC patients treated with chemotherapy, by country
Figure 110: Top three first-line regimens for mCRPC patients treated with therapies other than ADT or chemotherapy, by country
Figure 111: Top three second-line regimens for mCRPC patients treated with therapies other than ADT or chemotherapy, by country
Figure 112: Top three third-line regimens for mCRPC patients treated with therapies other than ADT or chemotherapy, by country
Figure 113: Trends in incident cases of diagnosed prostate cancer in the US, Japan, and five major EU markets, 2014–34
Figure 114: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 115: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 116: Jevtana for prostate cancer – SWOT analysis
Figure 117: The author's drug assessment summary of Jevtana for prostate cancer
Figure 118: The author's drug assessment summary of Jevtana for prostate cancer
Figure 119: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 120: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 121: Provenge for prostate cancer – SWOT analysis
Figure 122: The author's drug assessment summary of Provenge for prostate cancer
Figure 123: The author's drug assessment summary of Provenge for prostate cancer
Figure 124: Provenge sales for prostate cancer in the US, 2017–26
Figure 125: Trelstar sales for prostate cancer across the US and five major EU markets, by country, 2017–26
Figure 126: Xofigo for prostate cancer – SWOT analysis
Figure 127: The author's drug assessment summary of Xofigo for prostate cancer
Figure 128: The author's drug assessment summary of Xofigo for prostate cancer
Figure 129: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 130: Xtandi for prostate cancer – SWOT analysis
Figure 131: The author's drug assessment summary of Xtandi for prostate cancer
Figure 132: The author's drug assessment summary of Xtandi for prostate cancer
Figure 133: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 134: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 135: Zytiga for prostate cancer – SWOT analysis
Figure 136: The author's drug assessment summary of Zytiga for prostate cancer
Figure 137: The author's drug assessment summary of Zytiga for prostate cancer
Figure 138: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 139: Price sources and calculations, by country
Figure 140: DCVAC/PCa for prostate cancer – SWOT analysis
Figure 141: The author's drug assessment summary of DCVAC/PCa for prostate cancer
Figure 142: The author's drug assessment summary of DCVAC/PCa for prostate cancer
Figure 143: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 144: Lynparza for prostate cancer – SWOT analysis
Figure 145: The author's drug assessment summary of Lynparza for prostate cancer
Figure 146: The author's drug assessment summary of Lynparza for prostate cancer
Figure 147: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 148: Rubraca for prostate cancer – SWOT analysis
Figure 149: The author's drug assessment summary of Rubraca for prostate cancer
Figure 150: The author's drug assessment summary of Rubraca for prostate cancer
Figure 151: Rubraca sales for prostate cancer across the US and five major EU markets, by country, 2017–26
Figure 152: Tecentriq for prostate cancer – SWOT analysis
Figure 153: The author's drug assessment summary of Tecentriq for prostate cancer
Figure 154: The author's drug assessment summary of Tecentriq for prostate cancer
Figure 155: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 156: Yonsa for prostate cancer – SWOT analysis
Figure 157: The author's drug assessment summary of Yonsa for prostate cancer
Figure 158: The author's drug assessment summary of Yonsa for prostate cancer
Figure 159: Yonsa sales for prostate cancer in the US, 2017–26
Figure 160: Apalutamide for prostate cancer – SWOT analysis
Figure 161: The author's drug assessment summary of apalutamide for prostate cancer
Figure 162: The author's drug assessment summary of apalutamide for prostate cancer
Figure 163: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 164: Darolutamide for prostate cancer – SWOT analysis
Figure 165: The author's drug assessment summary of darolutamide for prostate cancer
Figure 166: The author's drug assessment summary of darolutamide for prostate cancer
Figure 167: Darolutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 168: Ipatasertib for prostate cancer – SWOT analysis
Figure 169: The author's drug assessment summary of ipatasertib for prostate cancer
Figure 170: The author's drug assessment summary of ipatasertib for prostate cancer
Figure 171: Ipatasertib sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 172: Masitinib for prostate cancer – SWOT analysis
Figure 173: The author's drug assessment summary of masitinib for prostate cancer
Figure 174: The author's drug assessment summary of masitinib for prostate cancer
Figure 175: Masitinib sales for prostate cancer across the five major EU markets, by country, 2017–26
Figure 176: Relugolix for prostate cancer – SWOT analysis
Figure 177: The author's drug assessment summary of relugolix for prostate cancer
Figure 178: The author's drug assessment summary of relugolix for prostate cancer
Figure 179: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26

Table 1: Prostate cancer sales across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Prostate cancer sales across the US, Japan, and five major EU markets, by class ($m), 2017–26
Table 3: Generics sales in prostate cancer across the US, Japan, and five major EU markets, by drug ($m), 2017–26
Table 4: Xtandi sales in prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Pipeline next-generation hormone therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug ($m), 2017–26
Table 6: Autologous vaccine sales in prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 7: Targeted pipeline therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug ($m), 2017–26
Table 8: Summary of drug classes and molecules included in The author's prostate cancer patient-based forecast
Table 9: Exchange rates used for calculating prices
Table 10: Oncologists and urologists surveyed for the prostate cancer primary research study, 2017
Table 11: DCVAC/PCa drug profile
Table 12: DCVAC/PCa Phase III trial in prostate cancer
Table 13: DCVAC/PCa Phase I/II data in prostate cancer
Table 14: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 15: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 16: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 17: Jevtana drug profile
Table 18: Jevtana pivotal Phase III data in prostate cancer
Table 19: Jevtana Phase III data in prostate cancer
Table 20: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 21: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 22: Lynparza drug profile
Table 23: Lynparza Phase III trial in prostate cancer
Table 24: Lynparza Phase II data in prostate cancer
Table 25: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 26: Provenge drug profile
Table 27: Provenge pivotal Phase III data in prostate cancer
Table 28: Provenge sales for prostate cancer in the US ($m), 2017–26
Table 29: Rubraca drug profile
Table 30: Rubraca trials in prostate cancer
Table 31: Rubraca sales for prostate cancer across the US and five major EU markets, by country ($m), 2017–26
Table 32: Tecentriq drug profile
Table 33: Tecentriq Phase III trials in prostate cancer
Table 34: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 35: Trelstar sales for prostate cancer across the US and five major EU markets, by country ($m), 2017–26
Table 36: Xofigo drug profile
Table 37: Xofigo Phase III data in prostate cancer
Table 38: Xofigo Phase III trials in prostate cancer
Table 39: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 40: Xtandi drug profile
Table 41: Xtandi Phase III data in prostate cancer
Table 42: Xtandi Phase III trials in prostate cancer
Table 43: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 44: Yonsa drug profile
Table 45: Yonsa Phase II/III trial in prostate cancer
Table 46: Yonsa sales for prostate cancer in the US ($m), 2017–26
Table 47: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 48: Zytiga drug profile
Table 49: Zytiga Phase III data in prostate cancer
Table 50: Zytiga Phase III trials in prostate cancer
Table 51: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 52: Apalutamide drug profile
Table 53: Apalutamide Phase III data in prostate cancer
Table 54: Apalutamide Phase I/II data in prostate cancer
Table 55: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 56: Darolutamide drug profile
Table 57: Darolutamide Phase III trials in prostate cancer
Table 58: Darolutamide Phase I/II data in prostate cancer
Table 59: Darolutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 60: Ipatasertib drug profile
Table 61: Ipatasertib Phase III trial in prostate cancer
Table 62: Ipatasertib Phase II data in prostate cancer
Table 63: Ipatasertib sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 64: Masitinib drug profile
Table 65: Masitinib Phase III trial in prostate cancer
Table 66: Masitinib Phase II data in prostate cancer
Table 67: Masitinib sales for prostate cancer across the five major EU markets, by country ($m), 2017–26
Table 68: Relugolix drug profile
Table 69: Relugolix Phase III trials in prostate cancer
Table 70: Relugolix Phase II data in prostate cancer
Table 71: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 72: Oncologists and urologists surveyed for the prostate cancer primary research study, 2017
Table 73: Percentage of US males who will develop prostate cancer over 10-, 20-, and 30-year intervals according to their current age, 2010–12
Table 74: Prostate cancer five-year relative survival rates in the US, by stage at diagnosis
Table 75: NCCN prostate cancer patient segmentation, by risk group
Table 76: ESMO prostate cancer patient segmentation, by risk group
Table 77: Prostate cancer segmentation using TNM stage, risk group, PSA measurement, and Gleason score
Table 78: Prostate cancer segmentation by clinical state
Table 79: Leading treatments for prostate cancer
Table 80: Cancer registry databases used as a source of prostate cancer incidence data, by country
Table 81: Forecasting methodology for prostate cancer incidence, by country, age group, and gender
Table 82: Sources of survival data used to estimate prostate cancer prevalence, by country
Table 83: Incident cases of prostate cancer in the US, Japan, and five major EU markets, by country, 2016–36
Table 84: Profiled key marketed drugs for prostate cancer
Table 85: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 86: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 87: Jevtana drug profile
Table 88: Jevtana pivotal Phase III data in prostate cancer
Table 89: Jevtana Phase III data in prostate cancer
Table 90: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 91: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 92: Provenge drug profile
Table 93: Provenge pivotal Phase III data in prostate cancer
Table 94: Provenge sales for prostate cancer in the US ($m), 2017–26
Table 95: Trelstar sales for prostate cancer across the US and five major EU markets, by country ($m), 2017–26
Table 96: Xofigo drug profile
Table 97: Xofigo Phase III data in prostate cancer
Table 98: Xofigo Phase III trials in prostate cancer
Table 99: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 100: Xtandi drug profile
Table 101: Xtandi Phase III data in prostate cancer
Table 102: Xtandi Phase III trials in prostate cancer
Table 103: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 104: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 105: Zytiga drug profile
Table 106: Zytiga Phase III data in prostate cancer
Table 107: Zytiga Phase III trials in prostate cancer
Table 108: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 109: Marketed prostate cancer products and approved indications in the US, Japan, and five major EU markets
Table 110: Restriction of Xofigo to the post-docetaxel setting in the five major EU markets, by country
Table 111: Reimbursement of Jevtana in the five major EU markets, by country
Table 112: Levers impacting access to prostate cancer drugs in the US and five major EU markets
Table 113: Importance of prostate cancer clinical trial endpoints in the US and five EU markets, by country
Table 114: Impact of Zytiga’s patent expiry on pipeline therapies targeting overlapping patient populations, by country
Table 115: Potential for contracting across the US and five major EU markets, by country
Table 116: Likely reimbursement of Zytiga in mHSPC
Table 117: Pricing and reimbursement of Erleada and Xtandi in nmCRPC, by country
Table 118: Likely reimbursement of DCVAC/PCa across the US and Europe, by country
Table 119: Pricing of key prostate cancer drugs in the US, Japan, and five major EU markets, by country
Table 120: Prior authorization criteria for prostate cancer drugs in selected formularies
Table 121: Prostate cancer clinical pathway used by Anthem’s Cancer Care Quality Program
Table 122: Formulary placement of prostate cancer drugs in selected commercial formularies
Table 123: Formulary placement of prostate cancer drugs in top nine Medicare Part D formularies
Table 124: Pan-Canadian Oncology Drug Review assessment of prostate cancer therapies
Table 125: Pricing premiums given to medicines that can demonstrate benefit over comparators
Table 126: Price calculation methodologies for prostate cancer drugs in Japan launched after 2008
Table 127: Transparency Committee's ASMR ratings and pricing implications
Table 128: Transparency Committee's SMR ratings and pricing implications
Table 129: Transparency Committee’s assessment of key prostate cancer therapies
Table 130: G-BA assessments of key prostate cancer therapies
Table 131: Reimbursement conditions for prostate cancer drugs in Italy
Table 132: Prostate cancer drug assessments by the Emilia-Romagna region
Table 133: Prostate cancer drug assessments by the Veneto region
Table 134: Spanish national and regional health reimbursement decisions for prostate cancer drugs
Table 135: NICE assessments for key prostate cancer therapies
Table 136: SMC assessments for key prostate cancer therapies
Table 137: Exchange rates used for calculating branded drug prices
Table 138: Profiled pipeline products in development for prostate cancer
Table 139: Typical Phase III clinical trial design in prostate cancer
Table 140: Late-stage compound that was recently discontinued for prostate cancer
Table 141: DCVAC/PCa drug profile
Table 142: DCVAC/PCa Phase III trial in prostate cancer
Table 143: DCVAC/PCa Phase I/II data in prostate cancer
Table 144: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 145: Lynparza drug profile
Table 146: Lynparza Phase III trial in prostate cancer
Table 147: Lynparza Phase II data in prostate cancer
Table 148: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 149: Rubraca drug profile